News

As at June 23, 2017

SaskWorks Diversified (Class A - Series A) $17.6803 SaskWorks Resources (Class R - Series A) $11.3422

SaskWorks Diversified (Class A - Series F) $18.2853 SaskWorks Resources (Class R - Series F) $11.6449

PFM CIO Opens Market with Cannimed

Brent Zettl, President and CEO, CanniMed Therapeutics Inc.(TSX:CMED) and Rob Duguid , Chief Investment Officer, PFM Capital Inc. joined Brady Fletcher, Managing Director, TSX Venture Exchange to open the market. CanniMed is a Canadian-based, international plant biopharmaceutical company with 15 years of pharmaceutical cannabis cultivation experience. The Company has a plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications. CanniMedTherapeutics Inc., will commence trading on Toronto Stock Exchange on December 29, 2016. For more information, please visit www.cannimed.ca

Back to News

Welcome

Please choose one of the following options to enter the site.

Search FAQs Advisor FAQs Legal Contact Facebook Logout

READ OUR PROSPECTUS > This offering is made only by prospectus. The prospectus contains important detailed information about the securities being offered. Copies of the prospectus may be obtained free of charge from your Investment Advisor or the agent, Industrial Alliance Securities Inc. (www.iavm.ca). Investors should read the prospectus and consult an Investment Advisor before making an investment decision.